Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor
- Registration Number
- NCT05301972
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This is an expanded access designed to provide access to Bromodomain and Extra-Terminal (BET) Inhibitor for eligible participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Bromodomain BET inhibitor mechanism action epigenetic regulation cancer therapy Bristol Myers Squibb
BET inhibitors clinical trials hematologic malignancies solid tumors efficacy BMS-986158 CC-90010
Predictive biomarkers BET inhibitor response resistance MYC BRD4 expression cancer patients
BET inhibitor class adverse events thrombocytopenia gastrointestinal toxicity management strategies clinical trials
BET inhibitor combination therapy PARP inhibitors immunotherapy oncology landscape competitor drugs development